AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 141 min read$INKT

Buell Jennifer sold $73K of INKT

Buell Jennifer (Chief Executive Officer) sold 6,938 shares of MiNK Therapeutics, Inc. (INKT) at $10.56 on 2026-10-12.

Original reporting
SEC EDGAR · Buell Jennifer
Published Oct 14, 2026, 6:36 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2026, 6:37 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$INKT
Neutral
high confidence
Mentioned
$INKT
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$INKTNeutralLow
01

Why it matters

The filing provides a factual update on insider holdings but does not introduce new strategic or financial information.

02

Market read

A small insider sale with limited market impact; primarily of interest to short‑term traders tracking insider activity.

03

What to watch

No material change in ownership; the CEO still holds a sizable stake.

Relevance 3/10Novelty 3/10Timing: after-market filing

Background

Form 4 filings disclose insider transactions; investors monitor them for potential signals.

Company-level read

Ticker impact

$INKTNeutralHigh confidence
Context

CEO Buell Jennifer sold 6,938 shares for $73,265, reducing her stake to 74,195 shares.

Expected impact

likely slight pressure as the market prices in the insider sell

Evidence & confidence

The transaction size is under $100k and represents a small fraction of total shares outstanding, so any impact will be minimal.

Market effects

Sector

None

Regional

None

Global

None

Counterpoint

What could challenge this read

The sale could be a routine liquidity move and not a negative signal.

Key entities

  • Company
    MiNK Therapeutics, Inc.

    Biotech firm listed on Nasdaq under ticker INKT.

  • Person
    Buell Jennifer

    Chief Executive Officer of MiNK Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

INKT insider trading history →

Related articles

AUG 13
$INKTMed

MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury

MiNK Therapeutics, Inc. (INKT) filed an SEC Form 8-K — Results of Operations and Financial Condition. MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury • First patients treated in randomized Phase 2 trial C-1300-02 were alive at Day 28, with improved oxygenation, infection contr

SEC EDGAR 8-K6 min
MAY 29
$SPRCMedAI 8/10

Top Biotech Gainers: SPRC Deal Gets Nod, CODX Rallies, OTLK, AKTX, FTRE Drawing Investor Interest

SciSparc (SPRC) shares rose ~140% after its TSX Venture subsidiary received conditional approval to buy ~54% of private Israeli CliniQuantum for 56.6M NeuroThera shares (~$9.46M). Co-Diagnostics (CODX) gained ~53% for a third day amid Ebola PCR assay progress. Akari (AKTX) jumped ~38% on ASCO abstract acceptance and new KRAS-mutant synergy data; Outlook (OTLK) rose ~26% ahead of a June FDA resubmission.

rttnews.com6 min